Investigational Drug Details
| Drug ID: | D351 |
| Drug Name: | Dexfenfluramine |
| Synonyms: | |
| Type: | small molecule |
| DrugBank ID: | DB01191 |
| DrugBank Description: | Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was withdrawn. |
| PubChem ID: | 66265 |
| CasNo: | 3239-44-9 |
| Repositioning for NAFLD: | Yes |
| SMILES: | CCN[C@@H](C)CC1=CC=CC(=C1)C(F)(F)F |
| Structure: |
|
| InChiKey: | DBGIVFWFUFKIQN-VIFPVBQESA-N |
| Molecular Weight: | 231.2573 |
| DrugBank Targets: | Sodium-dependent serotonin transporter; 5-hydroxytryptamine receptor 2C |
| DrugBank MoA: | Dexfenfluramine binds to the serotonin reuptake pump. This causes inhbition of serotonin reuptake. The increased levels of serotonin lead to greater serotonin receptor activation which in turn lead to enhancement of serotoninergic transmission in the centres of feeding behavior located in the hypothalamus. This suppresses the appetite for carbohydrates. |
| DrugBank Pharmacology: | Used to treat diabetes and obesity, Dexfenfluramine decreases caloric intake by increasing serotonin levels in the brain’s synapses. Dexfenfluramine acts as a serotonin reuptake inhibitor. It also causes release of serotonin from the synaptosomes. |
| DrugBank Indication: | For the management of obesity including weight loss and maintenance of weight loss in patients on a reduced calorie diet |
| Targets: | |
| Therapeutic Category: | |
| Clinical Trial Progress: | |
| Latest Progress: |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title |
|---|